NCT05622994

Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Efectos de un Antagonista/Agonista Inverso Del Receptor CB1 (Rimonabant) Sobre la Capacidad Para la deambulación en Lesionados Medulares Incompletos

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Hospital Nacional de Parapléjicos de Toledo · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo for the same period. Objective is to improve walking abilities of spinal cord injury individuals (incomplete lesions) and demonstrate that it is a safe treatment in spinal cord injury population.

Detailed description

This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo for the same period. Main goal are to test safety and efficacy (impairment of walking abilities teste with the 6 min walking test) of Rimonabant in a specific population (incomplete spinal cord injury).

Conditions

• Spinal Cord Injuries

Interventions

Type	Name	Description
DRUG	Rimonabant	Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.

Timeline

• Start date: 2022-11-01
• Primary completion: 2023-11-01
• Completion: 2023-11-01
• First posted: 2022-11-21
• Last updated: 2022-11-21

Locations

1 site across 1 country: Spain